GO:1990508 CKM complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990508 (CKM complex) is a cellular_component term describing a cyclin-dependent kinase complex that reversibly associates with the Mediator complex.
• In Saccharomyces cerevisiae the CKM complex consists of SSN2, SSN3, SSN8 and SRB8, and is also known as the CDK8 kinase module or SRB8/9/10/11 complex.
• The CKM complex is a reversible, context-dependent module of the Mediator coactivator, linking transcriptional regulation to kinase signaling.
• Because the term is a component rather than a disease, its disease relevance is indirect and must be inferred from the functions of its subunits and their orthologs.
• Research on CKM complex components relies on knockout, point-mutation, knock-in and overexpression models combined with transcriptomics and proteomics.
• The term should not be confused with the clinical Cardiovascular-Kidney-Metabolic (CKM) syndrome, which is an unrelated medical concept.
Description
GO:1990508, the CKM complex, is a Gene Ontology cellular_component term for a cyclin-dependent kinase complex that reversibly associates with the Mediator complex. The name CKM stands for CDK8 kinase module, and the complex is also known as the SRB8/9/10/11 complex or SRB8-SRB11 complex. In the budding yeast Saccharomyces cerevisiae, the complex is defined as consisting of SSN2, SSN3, SSN8 and SRB8. This makes GO:1990508 a precise, species-anchored annotation that describes a specific multiprotein assembly rather than a generic kinase activity. For researchers, the CKM complex matters because it represents a reversible interface between the Mediator coactivator and cyclin-dependent kinase signaling. Mediator is a central transcriptional coactivator, and the reversible association of a kinase module with it provides a mechanism for dynamic, signal-responsive control of gene expression. Because the annotation is defined by subunit composition and complex membership, it is directly testable by biochemical purification, affinity tagging and genetic perturbation. It is important to distinguish GO:1990508 from the clinical entity also abbreviated CKM, namely Cardiovascular-Kidney-Metabolic syndrome. The two share an acronym but are unrelated: one is a molecular machine in the nucleus, the other is a cardiometabolic risk construct used in epidemiology and prevention. This article concerns only the Gene Ontology term GO:1990508 and the genes and methods used to study it.
CKM complex At A Glance
| GO ID | GO:1990508 |
|---|---|
| GO term | CKM complex |
| Ontology | cellular_component |
| Synonym | CDK8 kinase module; SRB8/9/10/11 complex; SRB8-SRB11 complex |
| Definition | Cyclin-dependent kinase complex which reversibly associates with the Mediator complex; in Saccharomyces cerevisiae it consists of SSN2, SSN3, SSN8 and SRB8 |
| Major function | Reversible kinase module of the Mediator complex that modulates transcription |
| Representative subunits | SSN2, SSN3, SSN8, SRB8 in Saccharomyces cerevisiae |
| Assembly property | Reversible association with the Mediator complex |
| Typical study organisms | Saccharomyces cerevisiae and orthologous systems |
What Is GO:1990508?
In plain terms, GO:1990508 describes a kinase module that can attach to and detach from the Mediator complex. Formally, it is a cyclin-dependent kinase complex which reversibly associates with the Mediator complex, and in Saccharomyces cerevisiae it consists of SSN2, SSN3, SSN8 and SRB8. The term is a cellular_component annotation, meaning it describes where a set of proteins localizes and assembles rather than what reaction they catalyze. Its synonyms, CDK8 kinase module, SRB8/9/10/11 complex and SRB8-SRB11 complex, reflect historical genetic nomenclature from yeast suppressor and RNA polymerase II mediator studies.
Why Is CKM complex Important in Cell Biology?
The CKM complex is important because it defines a reversible, regulated module of the Mediator coactivator, which places kinase signaling directly at the heart of transcriptional control. Because the annotation specifies subunit composition and reversible association, it gives researchers a concrete, falsifiable target for biochemical and genetic experiments. Understanding this complex helps explain how cells tune gene expression programs in response to signals, and it provides a framework for comparing yeast and metazoan Mediator-associated kinases. At the same time, the acronym overlap with Cardiovascular-Kidney-Metabolic syndrome means that literature searches must be carefully scoped to avoid conflating a molecular complex with a clinical syndrome.
• Defines a specific multiprotein assembly rather than a vague kinase activity, enabling precise annotation.
• Links cyclin-dependent kinase signaling to the Mediator transcriptional coactivator.
• Provides a reversible module whose association with Mediator can be experimentally toggled.
• Supports comparative studies between yeast and metazoan Mediator kinase modules.
• Enables genetic dissection through the defined yeast subunits SSN2, SSN3, SSN8 and SRB8.
• Requires careful disambiguation from Cardiovascular-Kidney-Metabolic syndrome in literature searches.
• Offers a testable model for how signal-responsive transcription is achieved.
• Guides design of knockout, tagged knock-in and overexpression experiments.
CKM complex: Biological Process, Structure and Molecular Mechanism
What Happens During CKM complex Function?
In simple terms: The CKM complex acts like a removable control knob on the Mediator machine that helps switch genes on or off.
The CKM complex is defined by its reversible association with the Mediator complex, a central transcriptional coactivator. This reversible binding means the complex is not a permanent fixture of Mediator but a dynamic module that can join and leave the coactivator. In Saccharomyces cerevisiae, this module comprises SSN2, SSN3, SSN8 and SRB8, which together form a cyclin-dependent kinase complex. The functional consequence of this assembly is modulation of transcription at genes whose expression is controlled by Mediator.
Reversible Association with Mediator
In simple terms: The complex can dock onto Mediator and undock again, so its effect on genes can be turned on and off.
The defining property of GO:1990508 is that the cyclin-dependent kinase complex reversibly associates with the Mediator complex. Reversibility implies a regulated equilibrium between free and Mediator-bound states, which allows the cell to adjust transcriptional output without permanently altering the coactivator. Because the annotation explicitly includes this reversibility, experiments that measure binding stoichiometry, affinity or exchange are directly relevant to the term.
Subunit Composition in Saccharomyces cerevisiae
In simple terms: In yeast, four proteins named SSN2, SSN3, SSN8 and SRB8 come together to build this complex.
The QuickGO definition states that in Saccharomyces cerevisiae the CKM complex consists of SSN2, SSN3, SSN8 and SRB8. These four subunits are the minimal set required for the annotation, and their genetic names derive from suppressor and SRB screens. Any experimental claim about the yeast CKM complex should therefore account for all four subunits rather than a single component.
Molecular Mechanism of the Kinase Module
In simple terms: The complex uses a cyclin-dependent kinase to send signals that change how genes are read.
GO:1990508 is classified as a cyclin-dependent kinase complex, which means its core activity is phosphorylation mediated by a CDK subunit paired with a cyclin-like partner. In yeast, SSN3 provides the kinase catalytic subunit and SSN8 the cyclin-like partner, while SSN2 and SRB8 contribute structural and regulatory functions within the module. The module's reversible attachment to Mediator positions this kinase activity to influence transcription.
Regulation of CKM Complex Assembly
In simple terms: Whether the complex is attached to Mediator depends on cellular signals and the availability of its subunits.
Because the term is defined by reversible association, regulation of CKM complex function is expected to operate at the level of assembly and binding to Mediator. The presence and stoichiometry of SSN2, SSN3, SSN8 and SRB8 determine whether a functional module can form in Saccharomyces cerevisiae. Researchers should therefore treat complex abundance, subunit modification and Mediator occupancy as linked regulatory variables when studying GO:1990508.
Key Genes Involved in GO:1990508 CKM complex
The genes most directly associated with GO:1990508 are the Saccharomyces cerevisiae subunits named in the QuickGO definition, together with their commonly studied orthologs.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SSN3 | Cyclin-dependent kinase catalytic subunit of the yeast CKM complex | Core enzymatic component for kinase-activity studies |
| SSN8 | Cyclin-like partner of the kinase subunit in yeast | Required for formation of an active CDK module |
| SSN2 | Structural and regulatory subunit of the yeast CKM complex | Defines complex integrity and Mediator association |
| SRB8 | Subunit of the yeast CKM complex | Named in the GO definition; target for genetic perturbation |
| MED12 | Metazoan ortholog of the Mediator kinase module subunit | Comparative studies of Mediator kinase modules |
| MED13 | Metazoan ortholog of the Mediator kinase module subunit | Comparative studies of Mediator kinase modules |
| CDK8 | Metazoan kinase ortholog of the yeast module | Kinase-focused mechanistic studies |
| CCNC | Metazoan cyclin partner ortholog | Cyclin-dependent kinase regulation studies |
| MED1 | Core Mediator subunit interacting with the kinase module | Mediator interaction studies |
| MED17 | Core Mediator subunit | Mediator architecture studies |
| MED6 | Core Mediator subunit | Mediator architecture studies |
| MED8 | Core Mediator subunit | Mediator architecture studies |
| MED18 | Core Mediator subunit | Mediator architecture studies |
| MED20 | Core Mediator subunit | Mediator architecture studies |
| MED22 | Core Mediator subunit | Mediator architecture studies |
| MED30 | Core Mediator subunit | Mediator architecture studies |
| MED31 | Core Mediator subunit | Mediator architecture studies |
How Is CKM complex Regulated?
Regulation of GO:1990508 is intrinsic to its definition: the complex reversibly associates with the Mediator complex, so its regulatory logic is one of dynamic binding rather than permanent membership. In Saccharomyces cerevisiae, the availability and modification state of SSN2, SSN3, SSN8 and SRB8 will determine whether the module can assemble and dock onto Mediator. Because the annotation is a cellular_component term, regulation should be assessed by measuring complex formation, subunit stoichiometry and Mediator occupancy rather than by a single enzymatic readout. Comparative work in metazoan systems can reveal whether the same reversible logic applies to orthologous Mediator kinase modules.
CKM complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SSN3 | Transcriptional regulation via Mediator-associated kinase module | Yeast knockout and point-mutation models |
| SSN8 | Cyclin-dependent kinase module assembly | Yeast knockout and tagged knock-in models |
| SSN2 | Mediator kinase module integrity | Yeast knockout and affinity-purification models |
| SRB8 | Mediator-associated transcriptional control | Yeast knockout and overexpression models |
| CDK8 (ortholog) | Comparative Mediator kinase biology | Metazoan knockout and knock-in models |
Disambiguating CKM complex from Cardiovascular-Kidney-Metabolic Syndrome
The acronym CKM is heavily used in clinical literature for Cardiovascular-Kidney-Metabolic syndrome, a cardiometabolic risk construct with staged definitions and prevention implications. This clinical syndrome is unrelated to GO:1990508, which is a nuclear cyclin-dependent kinase complex associated with Mediator. Researchers searching for the Gene Ontology term must therefore use the GO ID or the synonyms CDK8 kinase module and SRB8/9/10/11 complex to avoid retrieving cardiometabolic epidemiology papers. Failure to disambiguate can lead to inappropriate citation of clinical cohort studies in molecular mechanism papers.
Mediator Kinase Modules and Transcriptional Dysregulation
Because GO:1990508 describes a reversible kinase module of the Mediator coactivator, its dysfunction is conceptually linked to transcriptional dysregulation rather than to a single named disease. Mediator-associated kinase modules are studied as regulators of gene expression programs, and perturbations of their subunits can alter transcriptional output. Any disease association must be established experimentally for the specific subunit and organism, and should not be assumed from the GO annotation alone. This is why the term is best treated as a mechanistic entry point for hypothesis generation.
Clinical CKM Syndrome as a Separate Research Domain
Clinical CKM syndrome research focuses on prevalence, staging, social determinants and cardiometabolic outcomes, and uses tools such as estimated glucose disposal rate and inflammation indices. Therapeutic reviews in this domain discuss novel cardiometabolic medications and heart failure prevention. None of these clinical concepts describe the molecular CKM complex of GO:1990508, and citations from this literature should only be used to clarify the acronym collision. Keeping the two domains separate is essential for accurate scientific communication.
From CKM complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the subunit required for CKM complex formation? | Knockout of SSN2, SSN3, SSN8 or SRB8 in Saccharomyces cerevisiae |
| Which residue is required for kinase activity? | Point mutation of the catalytic subunit SSN3 |
| Where does the complex bind Mediator? | Tagged knock-in of a subunit followed by affinity purification |
| Does excess subunit alter transcription? | Overexpression of individual CKM complex subunits |
| Is the association reversible? | Inducible or competition-based binding assays with tagged subunits |
| Are metazoan orthologs functionally equivalent? | Knockout or knock-in of CDK8, MED12 or MED13 orthologs |
How to Study the CKM complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Affinity purification plus mass spectrometry | Subunit composition and Mediator association | Validating GO:1990508 membership |
| RNA sequencing | Transcriptional changes after perturbation | Linking the complex to gene expression programs |
| Epistasis analysis | Genetic pathway relationships among subunits | Testing whether SSN2, SSN3, SSN8 and SRB8 act together |
| Fluorescence microscopy | Subcellular localization and co-localization | Assessing nuclear and Mediator-associated pools |
| Co-immunoprecipitation | Physical interaction between subunits | Confirming complex assembly |
| Western blotting | Subunit abundance and modification | Monitoring complex stoichiometry |
| Inducible expression systems | Dynamic changes in complex levels | Testing reversibility of association |
| Comparative genomics | Conservation of module subunits | Identifying metazoan orthologs |
Affinity Purification and Proteomics
Because GO:1990508 is defined by subunit composition and association with Mediator, affinity purification of tagged SSN2, SSN3, SSN8 or SRB8 followed by mass spectrometry is a direct way to test complex membership. Proteomic detection of core Mediator subunits in the same purifications supports the annotated interaction. Quantitative comparison of bound versus free subunit pools can address the reversibility built into the definition.
Transcriptomics after Subunit Perturbation
RNA sequencing of yeast strains lacking or overexpressing CKM complex subunits can reveal the transcriptional consequences of losing the module. Because the complex acts through Mediator, changes in Mediator-dependent gene programs are the expected readout. Pairing transcriptomics with binding data helps distinguish direct effects on Mediator from indirect cellular responses.
Genetic Interaction and Epistasis Analysis
Epistasis experiments among SSN2, SSN3, SSN8 and SRB8 can test whether the four subunits act in a single pathway, as implied by their shared annotation. Genetic interaction screens with core Mediator subunits can further map the functional interface. Such experiments are a classic way to validate a cellular_component annotation genetically.
Imaging and Subcellular Localization
Fluorescent tagging of CKM complex subunits allows their nuclear localization and co-localization with Mediator to be assessed in living cells. Dynamic imaging can in principle capture reversible association events at transcription sites. These approaches complement biochemical purification by providing spatial and temporal information.
How CRISPR Can Be Used to Study GO:1990508 CKM complex
Knockout
CRISPR knockout of SSN2, SSN3, SSN8 or SRB8 in Saccharomyces cerevisiae can abolish formation of the CKM complex and test which subunits are essential for the annotation. Loss-of-function strains provide a clean background for asking whether Mediator association and transcriptional regulation depend on the module. Knockout of metazoan orthologs such as CDK8, MED12 or MED13 enables comparative studies of Mediator kinase modules.
Point Mutation
Point mutations can be introduced into the catalytic subunit SSN3 to separate kinase activity from complex assembly. Such separation-of-function alleles help determine whether the phenotype of a knockout reflects loss of the whole module or loss of catalytic activity alone. Point mutations in interaction surfaces can similarly test which residues mediate reversible binding to Mediator.
Knock-in
Tagged knock-in of SSN2, SSN3, SSN8 or SRB8 allows endogenous-level purification and imaging of the CKM complex without overexpression artifacts. Knock-in of epitope or fluorescent tags supports affinity proteomics and live-cell localization studies. These models are particularly useful for measuring the reversible association with Mediator under native regulatory conditions.
Overexpression
Overexpression of individual CKM complex subunits can test whether excess subunit titrates partners or alters transcriptional output. Because the complex is defined by reversible association, overexpression may shift the equilibrium toward or away from Mediator-bound states. Overexpression models are therefore complementary to knockouts when studying GO:1990508.
How EDITGENE Supports CKM complex Research
Researchers studying CKM complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, Mediator association or transcriptional regulation, and this requires precise, isogenic cell models rather than correlative data alone. EDITGENE provides the genome engineering and screening tools needed to build such models for the subunits and orthologs of GO:1990508.
Contact EDITGENE today to design your custom CRISPR model for CKM complex research.
Frequently Asked Questions About CKM complex
What is the CKM complex (GO:1990508)?
GO:1990508 describes a cyclin-dependent kinase complex that reversibly associates with the Mediator complex; in Saccharomyces cerevisiae it consists of SSN2, SSN3, SSN8 and SRB8.
What genes are involved in the CKM complex?
In Saccharomyces cerevisiae the defining genes are SSN2, SSN3, SSN8 and SRB8, with metazoan orthologs such as CDK8, MED12 and MED13 studied comparatively.
Is the CKM complex the same as Cardiovascular-Kidney-Metabolic syndrome?
No. Cardiovascular-Kidney-Metabolic syndrome is a clinical cardiometabolic construct, whereas GO:1990508 is a nuclear Mediator-associated kinase complex; the shared acronym causes confusion.
What are the synonyms of GO:1990508?
The synonyms are CDK8 kinase module, SRB8/9/10/11 complex and SRB8-SRB11 complex.
What is the function of the CKM complex?
It acts as a reversible kinase module of the Mediator complex, modulating transcription through cyclin-dependent kinase activity.
Which organism defines the subunit composition of GO:1990508?
The QuickGO definition specifies Saccharomyces cerevisiae, where the complex consists of SSN2, SSN3, SSN8 and SRB8.
How can I study the CKM complex experimentally?
Affinity purification, RNA sequencing, epistasis analysis and imaging of tagged subunits are common approaches, complemented by CRISPR knockout and knock-in models.
Why is the CKM complex important for transcription?
Because it reversibly associates with the Mediator coactivator, it provides a dynamic link between kinase signaling and transcriptional regulation.
What CRISPR models are useful for CKM complex research?
Knockout, point-mutation, tagged knock-in and overexpression models of the subunit genes are all useful for dissecting complex assembly and function.
Does the CKM complex cause a specific disease?
The GO term itself is not a disease; any disease link must be established experimentally for specific subunits and should not be assumed from the annotation.
Conclusion
GO:1990508, the CKM complex, is a precisely defined cellular_component term for a cyclin-dependent kinase complex that reversibly associates with the Mediator complex and, in Saccharomyces cerevisiae, consists of SSN2, SSN3, SSN8 and SRB8. Its value to researchers lies in the clarity of its subunit composition and its explicit reversibility, which make it directly testable by biochemical and genetic methods. Careful disambiguation from Cardiovascular-Kidney-Metabolic syndrome is essential when searching the literature. By combining knockout, point-mutation, knock-in and overexpression models with transcriptomic, proteomic and imaging readouts, laboratories can dissect how this module assembles and how it influences transcription. EDITGENE supports these efforts with genome engineering and screening services tailored to CKM complex-related genes.
References
- 1. Sebastian SA et al.. 2024. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review.. Curr Probl Cardiol 49(2):102344 PMID: 38103820
- 2. Kittelson KS et al.. 2024. Cardiovascular-kidney-metabolic syndrome - An integrative review.. Prog Cardiovasc Dis 87:26-36 PMID: 39486671
- 3. Zhu R et al.. 2024. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health.. JAMA Netw Open 7(11):e2445309 PMID: 39556396
- 4. Pohlman N et al.. 2025. Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.. J Clin Endocrinol Metab 110(8):2105-2122 PMID: 40388382
- 5. Dong B et al.. 2025. Estimated glucose disposal rate outperforms other insulin resistance surrogates in predicting incident cardiovascular diseases in cardiovascular-kidney-metabolic syndrome stages 0-3 and the development of a machine learning prediction model: a nationwide prospective cohort study.. Cardiovasc Diabetol 24(1):163 PMID: 40241176
- 6. Chen Y et al.. 2025. Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in cardiovascular-kidney-metabolic syndrome stage 0-3: a nationwide prospective cohort study.. Cardiovasc Diabetol 24(1):147 PMID: 40158167
- 7. Ostrominski JW et al.. 2025. Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.. Lancet 406(10508):1171-1192 PMID: 40889511
- 8. Keogh MC et al.. 2025. A needed nomenclature for nucleosomes.. Mol Cell 85(19):3554-3561 PMID: 41043390
